NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share equaled $0.21 in the first quarter of fiscal 2013. Reported earnings per share in the first quarter of fiscal 2012 were $0.90 after a charge of $40.0 million or $0.14 per share net of tax, related to a new product licensing agreement with Blue Ash Therapeutics, LLC (Blue Ash) for azimilide, a novel antiarrhythmic agent. Excluding acquisition related amortization in both periods presented and the Blue Ash charge in last year’s first quarter, non-GAAP EPS in the first fiscal quarter of 2013 equaled $0.28 as compared with $1.07 in the first quarter of fiscal 2012.
